

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A24; B35, B49; Cw7, Cw9; DR4, DR13; DQ6, DQ7

Summary of Results					Summary of Results				
Total tested	20	20	20	20	15	15	15	15	
Positive	3	0	0	16	2	1	1	13	
Negative	17	20	20	4	13	14	14	2	
Not Tested	3	3	3	3	0	0	0	0	
% Positive	15.0%	0.0%	0.0%	80.0%	13.3%	6.7%	6.7%	86.7%	
% Negative	85.0%	100.0%	100.0%	20.0%	86.7%	93.3%	93.3%	13.3%	
Consensus	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
HLA Antibody (Defined By CDC)	A2, B17	DR3	DR3	B14+					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
11	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
12	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
14	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
15	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Serum 4 positive at dilution but not at neat
19	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
20	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
23	Negative	Negative	Negative	Positive					
24	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	Negative	Negative	Negative	Positive	Positive	Positive	Positive	Positive	
34	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
35	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
38	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
39	NT	NT	NT	NT					Not tested due to poor cell viability (<80%)
41	NT	NT	NT	NT					Poor sample quality
42	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
45	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
48	NT	NT	NT	NT					Samples delayed in post and cells not viable
51	Positive	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
54	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Background kill on T-cells was about 20%
58	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
62	Negative	Negative	Negative	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	0	0	0	0	0	0	0	27-Mar	28-Mar	Yes	Yes	90	Cedarlane	30	30	AO/PI	
11									26-Mar	27-Mar	Yes	Yes	99	Cedarlane	45	90	Fluoroquench	
12	5%	5%	5%	20%	5%	5%	5%	80%	26-Mar	26-Mar	Yes	Yes	95	Cedarlane	30	90	EB/AO	
14	0	0	0	8	0	0	0	8	26-Mar	26-Mar	Yes	Yes	90	Cedarlane	60	120	EB/AO	
15				2				2	26-Mar	26-Mar	Yes	Yes	95	Cedarlane	60	60	EB/AO	
19	1	0	0	3					26-Mar	27-Mar	Yes	No	90	Cedarlane	30	120	CFDA/EB	
20	1	1	1	8	1	1	1	6	26-Mar	26-Mar	Yes	Yes	90	Cedarlane	30	60	EB/AO	
23	1	1	1	4					26-Mar	26-Mar	Yes	Yes	90	Cedarlane	40	40	EB/AO	
24	10	10	10	20	40	25	30	90	26-Mar	27-Mar	Yes	Yes	90	Cedarlane	45	90	EB/AO	
25	1	1	1	1	1	1	1	1	26-Mar	26-Mar	Yes	Yes	99	Cedarlane	45	60	Fluoroquench	
28	1	1	1	4	2	2	2	6	26-Mar	26-Mar	Yes	Yes	90	Cedarlane	30	45	EB/AO	
34	1	1	1	4	1	1	1	6	26-Mar	26-Mar	Yes	Yes	99	Cedarlane	30	90	EB/AO	
35	8	1	1	8	1	1	1	8	26-Mar	27-Mar	Yes	Yes	80	70	Cedarlane	45	90	Fluoroquench
38	1	1	1	2	1	1	1	2	26-Mar	26-Mar	Yes	Yes	90	95	Cedarlane	60	60	EB/AO
39	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	26-Mar	Yes	No	<80	Cedarlane	45	90	EB/AO	
41	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	27-Mar	Yes	No	60	Cedarlane	60	60	EB/AO	
42				40-60%				40-60%	26-Mar	27-Mar	Yes	No	90	TCS Biosciences	60	120	EB/AO	
45	1	1	1	6	1	1	1	8	26-Mar	27-Mar	Yes	Yes	95	Cedarlane	60	90	EB/AO	
48	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	28-Mar	NT	NT	NT	NT	NT	NT	NT	
51	6	0	0	8	0	0	0	8	27-Mar	28-Mar	Yes	Yes	90	Cedarlane	60	60	Fluoroquench	
54	30	30	30	70					26-Mar	27-Mar	Yes	Yes	80	Cedarlane	60	60	PI	
58	5%	5%	5%	10%	5%	5%	5%	85%	26-Mar	26-Mar	Yes	Yes	95	Cedarlane	60	90	Fluoroquench	
62	1	1	1	6					26-Mar	26-Mar	Yes	Yes	90	Cedarlane	60	120	EB/AO	

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A24; B35, B49; Cw7, Cw9; DR4, DR13; DQ6, DQ7

Summary of Results					Summary of Results				
Total tested	17	17	16	17	11	12	12	12	
Positive	7	5	2	12	3	3	0	10	
Negative	10	12	14	5	8	9	12	2	
Not Tested	4	4	5	5	0	0	0	1	
% Positive	41.2%	29.4%	12.5%	70.6%	27.3%	25.0%	0.0%	83.3%	
% Negative	58.8%	70.6%	87.5%	29.4%	72.7%	75.0%	100.0%	16.7%	
Consensus	Not Assessed	Not Assessed	Negative	Not Assessed	Not Assessed	Negative	Negative	Positive	
HLA Antibody (Defined By CDC)	A2, B17	DR3	DR3	B14+					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT	Not tested - High background
11	Negative	Negative	Negative	Negative					
12	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
14	Positive	Positive	Positive	Positive	Positive	Positive	Negative	Positive	
15	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
19	Positive	Positive	NT	Positive					Serum 3 invalid due to error in droppiing cells
20	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
23	Positive	Negative	Positive	Positive					
24	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	NT	NT	NT	NT					Technically unsatisfactory. Very few cells ~60%
34	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Positive	
38	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
39	NT	NT	NT	NT					Not tested due to poor cell viability (<80%) Poor sample quality
41	NT	NT	NT	NT					
42	Negative	Negative	Negative	Weak Positive	Negative	Negative	Negative	Weak Positive	
45	Equivocal	Equivocal	Equivocal	Positive	Equivocal	Equivocal	Equivocal	Positive	This cell was of poor viability. Serum 4 was clearly positive, but serum 1, 2, +3 gave equivocal results
48	NT	NT	NT	NT					Samples delayed in post and cells not viable
51	Positive	Negative	Negative	Positive	Equivocal	Negative	Negative	Positive	
54	Positive	Positive	Negative	Positive					Low cell yield
58	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Positive	
62	Negative	Negative	Negative	Negative					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 03RD JUNE 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A04/2014

DESPATCHED ON 25TH MARCH 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	0	0	0	NT	0	0	0	NT	27-Mar	28-Mar	Yes	90	Cedarlane	30	30	AO/PI
11									26-Mar	27-Mar	Yes	95	Cedarlane	45	90	Fluoroquench
12	15%	15%	15%	40%	15%	15%	15%	80%	26-Mar	26-Mar	Yes	80	Cedarlane	30	60	EB/AO
14	6	6	4	8	4	2	0	8	26-Mar	26-Mar	Yes	90	Cedarlane	60	120	EB/AO
15				4				4	26-Mar	26-Mar	Yes	95	Cedarlane	60	60	EB/AO
19	5	5		8				8	26-Mar	27-Mar	Yes	90	Cedarlane	30	90	CFDA/EB
20	1	1	1	8	1	1	1	8	26-Mar	26-Mar	Yes	70	Cedarlane	30	60	EB/AO
23	4	1	4	6				6	26-Mar	26-Mar	Yes	90	Cedarlane	40	40	EB/AO
24	50	30	30	20	35	35	30	40	26-Mar	27-Mar	Yes	90	Cedarlane	45	90	EB/AO
25	1	1	1	1	1	1	1	1	26-Mar	26-Mar	Yes	99	Cedarlane	45	60	Fluoroquench
28	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	26-Mar	Yes		Cedarlane	30	45	EB/AO
34	2	4	1	4	2	2	1	4	26-Mar	26-Mar	Yes	95	Cedarlane	30	90	EB/AO
38	1	1	1	2	1	1	1	6	26-Mar	26-Mar	Yes	90	Cedarlane	60	60	EB/AO
39	NT	NT	NT	NT	NT	NT	NT	NT	26-Mar	26-Mar	Yes	<80	Cedarlane	45	90	EB/AO
41	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	27-Mar	Yes	50	Cedarlane	45	45	EB/AO
42				20%				20%	26-Mar	27-Mar	Yes	95	TCS Biosciences	60	60	EB/AO
45				6				6	26-Mar	27-Mar	Yes	70	Cedarlane	30	75	EB/AO
48	NT	NT	NT	NT	NT	NT	NT	NT	27-Mar	28-Mar	NT	NT	NT	NT	NT	NT
51	8	0	0	8	2	0	0	8	27-Mar	28-Mar	Yes	90	Cedarlane	60	60	Fluoroquench
54	100	80	20	70				70	26-Mar	27-Mar	Yes	>90	Cedarlane	60	60	PI
58	60%	30%	5%	5%	90%	80%	5%	60%	26-Mar	26-Mar	Yes	95	Cedarlane	60	90	Fluoroquench
62									26-Mar	26-Mar	Yes	80	One Lambda	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate